arGEN-X BV – Product Pipeline Review

Global Markets Direct’s, ‘arGEN-X BV – Product Pipeline Review – 2016’, provides an overview of the arGEN-X BV’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by arGEN-X BV, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of arGEN-X BV

The report provides overview of arGEN-X BV including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses arGEN-X BV’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features arGEN-X BV’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate arGEN-X BV’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for arGEN-X BV

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding arGEN-X BV’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

arGEN-X BV Snapshot 5

arGEN-X BV Overview 5

Key Information 5

Key Facts 5

arGEN-X BV - Research and Development Overview 6

Key Therapeutic Areas 6

arGEN-X BV - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Partnered Products 11

Partnered Products/Combination Treatment Modalities 12

Pipeline Products - Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

arGEN-X BV - Pipeline Products Glance 15

arGEN-X BV - Clinical Stage Pipeline Products 15

Phase I Products/Combination Treatment Modalities 15

arGEN-X BV - Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Discovery Products/Combination Treatment Modalities 17

arGEN-X BV - Drug Profiles 18

ARGX-110 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

ARGX-111 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

ARGX-113 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

ARGX-112 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

ARGX-115 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Monoclonal Antibodies for Cancer, Immunology and Metabolic Disorders 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Monoclonal Antibody for Skin Inflammation 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Monoclonal Antibodies to Block Nav1.7 for Chronic Pain 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

arGEN-X BV - Pipeline Analysis 31

arGEN-X BV - Pipeline Products by Target 31

arGEN-X BV - Pipeline Products by Route of Administration 32

arGEN-X BV - Pipeline Products by Molecule Type 33

arGEN-X BV - Pipeline Products by Mechanism of Action 34

arGEN-X BV - Recent Pipeline Updates 35

arGEN-X BV - Dormant Projects 39

arGEN-X BV - Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

List of Tables

arGEN-X BV, Key Information 5

arGEN-X BV, Key Facts 5

arGEN-X BV – Pipeline by Indication, 2016 7

arGEN-X BV – Pipeline by Stage of Development, 2016 9

arGEN-X BV – Monotherapy Products in Pipeline, 2016 10

arGEN-X BV – Partnered Products in Pipeline, 2016 11

arGEN-X BV – Partnered Products/ Combination Treatment Modalities, 2016 12

arGEN-X BV – Out-Licensed Products in Pipeline, 2016 13

arGEN-X BV – Out-Licensed Products/ Combination Treatment Modalities, 2016 14

arGEN-X BV – Phase I, 2016 15

arGEN-X BV – Preclinical, 2016 16

arGEN-X BV – Discovery, 2016 17

arGEN-X BV – Pipeline by Target, 2016 31

arGEN-X BV – Pipeline by Route of Administration, 2016 32

arGEN-X BV – Pipeline by Molecule Type, 2016 33

arGEN-X BV – Pipeline Products by Mechanism of Action, 2016 34

arGEN-X BV – Recent Pipeline Updates, 2016 35

arGEN-X BV – Dormant Developmental Projects,2016 39

arGEN-X BV, Subsidiaries 40

List of Figures

List of Figures

arGEN-X BV – Pipeline by Top 10 Indication, 2016 7

arGEN-X BV – Pipeline by Stage of Development, 2016 9

arGEN-X BV – Monotherapy Products in Pipeline, 2016 10

arGEN-X BV – Partnered Products in Pipeline, 2016 11

arGEN-X BV – Out-Licensed Products in Pipeline, 2016 13

arGEN-X BV – Pipeline by Target, 2016 31

arGEN-X BV – Pipeline by Route of Administration, 2016 32

arGEN-X BV – Pipeline by Molecule Type, 2016 33

arGEN-X BV – Pipeline Products by Mechanism of Action, 2016 34

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports